keyword
MENU ▼
Read by QxMD icon Read
search

ALCL

keyword
https://www.readbyqxmd.com/read/29689246/il-13-is-produced-by-tumor-cells-in-breast-implant-associated-anaplastic-large-cell-lymphoma-implications-for-pathogenesis
#1
Marshall E Kadin, John Morgan, Haiying Xu, Alan L Epstein, David Sieber, Bradley A Hubbard, William P Adams, Carlos E Bacchi, Joao C S Goes, Mark W Clemens, L Jeffrey Medeiros, Roberto N Miranda
More than 500 women worldwide have developed a CD30+ T-cell lymphoma around breast implants, strongly suggesting a cause and effect relationship, and designated as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The mechanism of lymphomagenesis is unknown. Recently, a bacterial biofilm containing gram negative bacilli was discovered on the surface of breast implants associated with ALCL. We and others have described overexpression of the proto-oncogene JUNB and mutations of JAK1/2, TP53 and STAT3 in BIA-ALCL...
April 21, 2018: Human Pathology
https://www.readbyqxmd.com/read/29663705/bronchial-brush-cytology-of-primary-anaplastic-large-cell-lymphoma-of-lung
#2
Meyyappa Devan Rajagopal, Debasis Gochhait, Bheemanathi Hanuman Srinivas, Rajesh Nachiappa Ganesh, Neelaiah Siddaraju, Manju Rajaram
Primary pulmonary lymphoma is defined as clonal lymphoid proliferation affecting one or both lungs in a patient with no extrapulmonary involvement at the time of diagnosis or during the subsequent 3 months. Anaplastic large cell lymphoma (ALCL) is a rare T-cell neoplasm which occurs as two distinct clinical entities-cutaneous and systemic variant. Primary lung involvement is extremely uncommon. It can be classified on the basis of being positive or negative for ALK rearrangement which carries prognostic significance...
April 16, 2018: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29662618/ectopic-expression-of-transcription-factor-batf3-induces-b-cell-lymphomas-in-a-murine-b-cell-transplantation-model
#3
Christian Weiser, Mina V Petkova, Benjamin Rengstl, Claudia Döring, Dorothee von Laer, Sylvia Hartmann, Ralf Küppers, Martin-Leo Hansmann, Sebastian Newrzela
The mechanisms involved in malignant transformation of mature B and T lymphocytes are still poorly understood. In a previous study, we compared gene expression profiles of the tumor cells of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) to their normal cellular counterparts and found the basic leucine zipper protein ATF-like 3 (BATF3) to be significantly upregulated in the tumor cells of both entities. To assess the oncogenic potential of BATF3 in lymphomagenesis and to dissect the molecular interactions of BATF3 in lymphoma cells, we retrovirally transduced murine mature T and B cells with a BATF3-encoding viral vector and transplanted each population into Rag1-deficient recipients...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29660984/chemically-induced-degradation-of-anaplastic-lymphoma-kinase-alk
#4
Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Amanda Loehr, Magda Bahcall, Eric S Fischer, Pasi A Janne, Rani E George, Nathanael S Gray
We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1)...
April 16, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29659699/a-different-perspective-on-breast-implant-surface-texturization-and-anaplastic-large-cell-lymphoma-alcl
#5
Tim Brown, Fraser Harvie, Sharon Stewart
Anaplastic large cell lymphoma (ALCL) is a rare form of lymphoma involving cells of the immune system. It is currently gaining interest because of an association between the development of ALCL and an increased risk in women who have had breast implant surgery. Although not confirmed, many theories exist as to the etiology of this association in women, and there is growing concern that ALCL is more prevalent in women with textured breast implants. In particular, the risk of developing ALCL appears to be related to increasing implant texturization or "surface roughness...
April 6, 2018: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29642597/immune-response-against-alk-in-children-with-alk-positive-anaplastic-large-cell-lymphoma
#6
REVIEW
Serena Stadler, Vijay Kumar Singh, Fabian Knörr, Christine Damm-Welk, Wilhelm Woessmann
Patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) mount a humoral and cellular immune response against ALK. More than 90% of children and adolescents with ALK-positive ALCL have detectable anti-ALK antibodies in serum or plasma, and the antibody titer inversely correlates with the risk of relapse. ALK-specific CD8 and CD4 T cell responses have been described in patients with ALK-positive ALCL. Vaccination with ALK DNA led to protection against lymphoma growth in a murine model...
April 10, 2018: Cancers
https://www.readbyqxmd.com/read/29617304/the-pathological-spectrum-of-systemic-anaplastic-large-cell-lymphoma-alcl
#7
REVIEW
Ivonne A Montes-Mojarro, Julia Steinhilber, Irina Bonzheim, Leticia Quintanilla-Martinez, Falko Fend
Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis. The recognition of anaplastic lymphoma kinase (ALK) fusion proteins as a result of chromosomal translocations or inversions was the starting point for the distinction of different subgroups of ALCL. According to their distinct clinical settings and molecular findings, the 2016 revised World Health Organization (WHO) classification recognizes four different entities: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negative ALCL (ALK− ALCL), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL), the latter included as a provisional entity...
April 4, 2018: Cancers
https://www.readbyqxmd.com/read/29614805/-27-al-nmr-study-of-the-ph-dependent-hydrolysis-products-of-al%C3%A2-so%C3%A2-%C3%A2-in-different-physiological-media
#8
Svend Berger, Jürgen Nolde, Timucin Yüksel, Wolfgang Tremel, Mihail Mondeshki
Soluble inorganic aluminium compounds like aluminium sulfate or aluminium chloride have been challenged by the European Chemical Agency to induce germ cell mutagenicity. Before conducting mutagenicity tests, the hydrolysis products in water and in physiological solutions should be determined as a function of the concentration and pH. We used different27 Al NMR spectroscopic techniques (heteronuclear Overhauser effect spectroscopy (HOESY), exchange spectroscopy (EXSY), diffusion ordered (DOSY)) in this work to gain the information to study the aluminium species in solutions with Al₂(SO₄)₃ concentrations of 50...
April 2, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29609590/oxidative-stress-enhances-tumorigenicity-and-stem-like-features-via-the-activation-of-the-wnt-%C3%AE-catenin-myc-sox2-axis-in-alk-positive-anaplastic-large-cell-lymphoma
#9
Chengsheng Wu, Nidhi Gupta, Yung-Hsing Huang, Hai-Feng Zhang, Abdulraheem Alshareef, Alexandra Chow, Raymond Lai
BACKGROUND: The phenomenon that malignant cells can acquire stemness under specific stimuli, encompassed under the concept of cancer cell plasticity, has been well-described in epithelial malignancies. To our knowledge, cancer cell plasticity has not yet been described in hematopoietic cancers. To illustrate and study cancer cell plasticity in hematopoietic cancers, we employed an in-vitro experimental model of ALK-positive anaplastic large-cell lymphoma (ALK+ALCL) that is based on the phenotypic and functional dichotomy of these cells, with cells responsive to a Sox2 reporter (i...
April 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29607225/breast-implant-associated-anaplastic-large-cell-lymphoma-case-report-and-review-of-the-literature
#10
Eva Berlin, Kunwar Singh, Christopher Mills, Ilan Shapira, Richard L Bakst, Manjeet Chadha
We are reporting the case of a 58-year-old woman with history of bilateral silicone breast implants for cosmetic augmentation. At 2-year interval from receiving the breast implants, she presented with swelling of the right breast with associated chest wall mass, effusion around the implant, and axillary lymphadenopathy. Pathology confirmed breast implant-associated anaplastic large cell lymphoma (stage III, T4N2M0, using BIA-ALCL TNM staging and stage IIAE, using Ann-Arbor staging). The patient underwent bilateral capsulectomy and right partial mastectomy with excision of the right breast mass and received adjuvant CHOP chemotherapy and radiation to the right breast and regional nodes...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29602182/disease-site-as-a-determinant-of-survival-outcome-in-patients-with-systemic-anaplastic-lymphoma-kinase-positive-anaplastic-large-cell-lymphoma-with-extranodal-involvement-an-analysis-of-1306-cases-from-the-us-national-cancer-database
#11
Kevin A Nguyen, Chang Su, Harrison X Bai, Zishu Zhang, Rong Xiao, Giorgos Karakousis, Paul J Zhang, Guiying Zhang
Systemic anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma with extranodal involvement (ALCL-E) is a rare form of non-Hodgkin lymphoma. No large study in the literature has compared the survival outcomes among different primary extranodal sites of involvement in ALK+ ALCL-E. We identified 1306 patients with ALK+ ALCL-E diagnosed between 2004 and 2014 in the US National Cancer Database, among whom 387 had primary extranodal site in the chest/abdomen/pelvis, 103 in the bone, 62 in the central nervous system, 134 in the head and neck and 620 in the cutaneous/soft tissue...
March 30, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29601554/treatment-options-for-paediatric-anaplastic-large-cell-lymphoma-alcl-current-standard-and-beyond
#12
REVIEW
Nina Prokoph, Hugo Larose, Megan S Lim, G A Amos Burke, Suzanne D Turner
Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65-90% of patients. Over the last two decades, major efforts have focused on improving the survival rate by intensification of combination chemotherapy regimens and employing stem cell transplantation for chemotherapy-resistant patients. More recently, several new and 'renewed' agents have offered the opportunity for a change in the paradigm for the management of both chemo-sensitive and chemo-resistant forms of ALCL...
March 30, 2018: Cancers
https://www.readbyqxmd.com/read/29595739/how-to-diagnose-and-treat-breast-implant-associated-anaplastic-large-cell-lymphoma
#13
Mark W Clemens, Garry S Brody, Raman C Mahabir, Roberto N Miranda
LEARNING OBJECTIVES: After reading this article, the participant should be able to: 1. Describe the diagnostic criteria for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL). 2. Appropriately evaluate a patient with suspected BIA-ALCL, including appropriate imaging, laboratory tests, and pathologic evaluation. 3. Understand the operative treatment of BIA-ALCL, and indications for systemic chemotherapy and/or radiation therapy in advanced disease. 4. Understand treatment outcomes and prognosis based on stage of disease...
April 2018: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/29588546/the-ap-1-batf-and-batf3-module-is-essential-for-growth-survival-and-th17-ilc3-skewing-of-anaplastic-large-cell-lymphoma
#14
Nikolai Schleussner, Olaf Merkel, Mariantonia Costanza, Huan-Chang Liang, Franziska Hummel, Chiara Romagnani, Pawel Durek, Ioannis Anagnostopoulos, Michael Hummel, Korinna Jöhrens, Antonia Niedobitek, Patrick R Griffin, Roberto Piva, Henrike L Sczakiel, Wilhelm Woessmann, Christine Damm-Welk, Christian Hinze, Dagmar Stoiber, Bernd Gillissen, Suzanne D Turner, Eva Kaergel, Linda von Hoff, Michael Grau, Georg Lenz, Bernd Dörken, Claus Scheidereit, Lukas Kenner, Martin Janz, Stephan Mathas
Transcription factor AP-1 is constitutively activated and IRF4 drives growth and survival in ALK+ and ALK- anaplastic large cell lymphoma (ALCL). Here we demonstrate high-level BATF and BATF3 expression in ALCL. Both BATFs bind classical AP-1 motifs and interact with in ALCL deregulated AP-1 factors. Together with IRF4, they co-occupy AP-1-IRF composite elements, differentiating ALCL from non-ALCL. Gene-specific inactivation of BATFs, or global AP-1 inhibition results in ALCL growth retardation and/or cell death in vitro and in vivo...
March 28, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29581862/doxorubicin-induced-loss-of-dna-topoisomerase-ii-and-dnmt1-dependent-suppression-of-mir-125b-induces-chemoresistance-in-alk-positive-cells
#15
Annabelle Congras, Nina Caillet, Nouritza Torossian, Cathy Quelen, Camille Daugrois, Pierre Brousset, Laurence Lamant, Fabienne Meggetto, Coralie Hoareau-Aveilla
Systemic anaplastic large-cell lymphoma (ALCL) is a childhood T cell neoplasm defined by the presence or absence of translocations that lead to the ectopic expression of anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK (NPM-ALK) fusions being the most common. Polychemotherapy involving doxorubicin is the standard first-line treatment but for the 25 to 35% of patients who relapse and develop resistance the prognosis remains poor. We studied the potential role of the microRNA miR-125b in the development of resistance to doxorubicin in NPM-ALK(+) ALCL...
March 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29562445/-expressions-and-clinical-significance-of-gas1-il-1rap-and-prf1-in-patients-with-alk-positive-anaplastic-large-cell-lymphoma
#16
Y Jiang, D Cao, C G Xu
Objective: To investigate the expressions of growth arrest-specific protein (GAS1), IL-1 receptor accessory protein (IL-1RAP) and perforin (PRF1) in patients with anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL) and their relationships with clinical significances and the prognoses of ALK+ ALCL. Methods: Twenty-six formalin-fixed paraffin-embedded (FFPE) samples of ALK+ ALCL patients who were diagnosed from January 2011 to September 2016 were collected. Twelve FFPE samples of patients with ALK+ ALCL, 13 FFPE samples of patients with peripheral T cell lymphoma (not otherwise specified) (PTCL-NOS) and 8 FFPE samples of patients with angioimmunoblastic T-cell lymphoma (AITL) were used as control groups...
February 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29549411/the-impact-of-stem-cell-transplantation-on-the-natural-course-of-peripheral-t-cell-lymphoma-a-real-world-experience
#17
Sarah Rohlfing, Sascha Dietrich, Mathias Witzens-Harig, Ute Hegenbart, Stefan Schönland, Thomas Luft, Anthony D Ho, Peter Dreger
The role of autologous stem cell transplantation (autoSCT) as consolidating treatment for peripheral T-cell lymphoma (PTCL) is unsettled. The aim of this analysis was to investigate the impact of autoSCT in the upfront setting by intent-to-treat and to study salvage strategies after relapse. Retrospective follow-up of all patients aged 18-70 years and treated at our institution for ALK-PTCL diagnosed between 2001 and 2014. Of 117 eligible patients, diagnosis was PTCL-NOS in 34, ALCL ALK- in 31, AITL in 28, and other PTCL in 24 patients...
March 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29538376/the-risk-of-central-nervous-system-relapses-in-patients-with-peripheral-t-cell-lymphoma
#18
Dai Chihara, Michelle A Fanale, Roberto N Miranda, Mansoor Noorani, Jason R Westin, Loretta J Nastoupil, Fredrick B Hagemeister, Luis E Fayad, Jorge E Romaguera, Felipe Samaniego, Francesco Turturro, Hun J Lee, Sattva S Neelapu, M Alma Rodriguez, Michael Wang, Nathan H Fowler, Richard E Davis, L Jeffrey Medeiros, Yasuhiro Oki
We performed a retrospective analysis to identify risk factors and survival outcome for central nervous system (CNS) relapse of peripheral T-cell lymphoma (PTCL) by histologic type. Records of 600 PTCL patients diagnosed between 1999 and 2014 were analyzed including PTCL not otherwise specified (PTCL-NOS, 174 patients), angoimmunoblastic T-cell lymphoma (AITL, 144), ALK+anaplastic large cell lymphoma (ALCL, 74), ALK-ALCL (103), extranodal NK-cell lymphoma (ENKL, 54), or others (51). With a median follow up of 57 months, 13 patients (4 PTCL-NOS, 1 AITL, 4 ALK+ALCL, 2 ALK-ALCL, 2 ENKL) experienced CNS relapse...
2018: PloS One
https://www.readbyqxmd.com/read/29516333/update-on-the-treatment-of-anaplastic-large-cell-lymphoma
#19
REVIEW
Khoan Vu, Weiyun Ai
PURPOSE OF REVIEW: Given the rarity of anaplastic large cell lymphoma (ALCL), studies evaluating new therapies have typically grouped ALCL together with other peripheral T cell lymphomas (PTCL). Thus, the treatment paradigm for ALCL largely mirrors that of PTCL in general. In this review, we discuss the current standard of care as well as emerging therapies, including antibody-based drugs, in systemic ALCL as well as primary cutaneous and breast implant-associated ALCL. RECENT FINDINGS: High CD30 expression in ALCL has allowed the use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in both systemic and primary cutaneous ALCL...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29515072/-long-term-administration-of-brentuximab-vedotin-in-a-patient-with-primary-cutaneous-anaplastic-large-cell-lymphoma-with-peripheral-blood-involvement-with-leukemic-change
#20
Hanae Kumekawa, Daisuke Mizuchi, Mitsuko Iiyama
We report a case of long-term administration of brentuximab vedotin (BV) for primary cutaneous anaplastic large cell lymphoma (pc-ALCL) with leukemic change. A 67-year-old man with lymphadenopathy was admitted to our hospital. Six years ago, he was diagnosed with pc-ALCL at another hospital, and complete remission was achieved with radiation therapy. We performed a biopsy of his lymph node and diagnosed the recurrence of pc-ALCL with leukemic change. Initially, CHOP and GCD regimens were ineffective; however, partial remission was achieved following BV therapy...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
keyword
keyword
105270
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"